The Myokinib monograph: operationalizing oncology’s highest-value systemic therapeutic

Introduction

In the era of precision oncology, the standard for introducing a new systemic therapeutic is ostensibly rigorous. Typically, a novel agent must demonstrate clinical efficacy alongside a manageable toxicity profile and a plausible mechanism of action. Yet while novel agents frequently fall short of these benchmarks, one host-directed intervention has quietly met them. Evidence synthesis from major oncology organizations and large observational cohorts consistently associates a host-directed intervention with improved outcomes across multiple solid tumors, and Phase III randomized evidence now substantiates the survival signal in at least one disease setting.^1,2

We propose designating this intervention, defined as structured exercise, as “Myokinib”. The suffix “-inib” is deliberate, denoting a kinase inhibitor. While conventional kinase inhibitors directly block enzymatic activity, the physiological cascade initiated by structured exercise achieves a functionally analogous outcome through a different route. By enhancing peripheral glucose disposal and reducing circulating insulin and IGF-1, Myokinib attenuates downstream signaling through the PI3K/Akt/mTOR axis, which is the same pathway targeted by multi-billion-dollar drug discovery programs³—programs often associated with significant financial hardship for survivors.⁴ This nomenclature is more than a metaphor; it is a prerequisite for clinical integration. Exercise has historically lacked the nominal legitimacy required to trigger the standard infrastructure of cancer care: a discrete place in the order set, a structured field in the electronic health record (EHR), and a formal line in the therapeutic formulary. Myokinib is an attempt to align the classification of this host-directed therapy with its demonstrated clinical value.

Despite epidemiological data suggesting that high-dose adherence to Myokinib is associated with a 30% to 50% reduction in cancer-specific mortality,^5,6 it remains absent from most tumor board recommendations and prescription forms. It is often relegated to brief lifestyle advice, not because oncologists doubt its value, but because the care system classifies it outside the formal therapeutic armamentarium. This systematic under-prescription reflects a classification failure in oncology care delivery. As Schmitz and Ligibel recently noted, if exercise were a pill, we would all prescribe it—but it is not, and therein lies the implementation challenge.⁷ We propose that the solution is not to abandon the pharmacologic frame but to complete it: to give exercise a name, a mechanism, a dose, and a place in the formulary. This commentary argues that treating exercise not as adjunct lifestyle advice but as a first-line systemic agent may help close the gap between guideline endorsement and clinical implementation (Figure 1).

Figure 1.

From recommendation to prescription: reclassifying structured exercise as Myokinib. (A) The clinical status quo treats exercise as lifestyle advice, creating a delivery gap where therapy is recommended but rarely prescribed. (B) Reclassification as systemic therapy enables EHR integration, standardized dosing, adherence monitoring, and quality tracking—with a zero-mile supply chain suitable for global implementation.

Pharmacodynamics

Mechanism of action

The pharmacodynamic profile of Myokinib is characterized by systemic, pleiotropic modulation of host-tumor signaling. Its action as an endogenous inhibitor of the metabolic growth factor axis, specifically the insulin/IGF-1 and PI3K/Akt/mTOR pathways, provides the rationale for kinase-inhibitor nomenclature. However, clinical efficacy likely derives from multi-targeted mechanisms, including immunomodulation, suppression of chronic inflammation, and increased mechanical shear stress on circulating tumor cells.^8,9 The precise contribution of each pathway and their interactions across tumor types and treatment contexts remain incompletely characterized.⁸

Clinical efficacy profile

If Myokinib were a patentable molecular entity with a comparable survival benefit, it would undoubtedly attract commercial sponsors and expedited regulatory review. Historically, critics cited the reliance on observational data as a barrier to adoption. That barrier has now fallen.

Large prospective cohorts consistently associate higher post-diagnosis physical activity with 30%-40% reductions in cancer-specific mortality across breast, colorectal, and other common solid tumors (Table 1).^2,5,10–12 The CHALLENGE trial, the first Phase 3 randomized study to establish survival benefits for structured exercise in a solid tumor, provides the confirmatory evidence. Participants with resected stage II-III colon cancer randomized to a structured exercise program versus health education demonstrated improved disease-free survival (hazard ratio 0.72) and overall survival (hazard ratio 0.63).¹³ Critically, these participants were already receiving standard adjuvant therapy; Myokinib is adjunctive, not alternative. For context, this disease-free survival benefit rivals the addition of oxaliplatin to fluoropyrimidine chemotherapy, at zero drug cost.

Table 1.

Key evidence supporting the clinical efficacy of structured exercise (Myokinib) in cancer survivorship.

Study	Design	Cancer type	N	Intervention	Survival HR (95% CI)	Absolute benefit	QoL/function
Courneya et al. 2025 (CHALLENGE)13 , a	Phase III RCT	Colon (Stage II -III)	889	Structured aerobic exercise vs health education	DFS: 0.72 (0.55-0.94) OS: 0.63 (0.43-0.94)	5-year DFS: 80.3% vs 73.9% (Δ6.4%) 8-year OS: 90.3% vs 83.2% (Δ7.1%)	Sustained improvement in SF-36 physical function to 3 years
Brown et al. 2023 (CALGB/SWOG 80702)11	Prospective within RCT	Colon (Stage III)	1696	≥18 MET-h/wk vs <3	DFS: 0.52 (0.36-0.70)	3-year DFS: 87.1% vs 76.5% (Δ10.6%)	—
Holmes et al. 2005 5	Prospective cohort	Breast (Stage I-III)	2,987	≥9 vs <9 MET-h/wk	Cancer mortality: 0.63 (0.48-0.81)	NRb	—
Meyerhardt et al. 2006 2	Prospective cohort	Colorectal (Stage I-III)	573	≥18 vs <3 MET-h/wk	Cancer mortality: 0.39 (0.18-0.82) All-cause: 0.43 (0.25-0.74)	NR	—
Kenfield et al. 2011 12	Prospective cohort	Prostate (non-metastatic)	2705	≥3 vs <1 h/wk vigorous activity	Cancer: 0.39 (0.18-0.84) All-cause: 0.51 (0.36-0.72)	NR	—

Abbreviations: CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; MET, metabolic equivalent task; NR, not reported; OS, overall survival; PF, physical function; QoL, quality of life; RCT, randomized controlled trial; SF-36, Short Form Health Survey-36.

 ^aOnly Phase III RCT with disease-free survival as a primary endpoint; all other studies are prospective observational.

 ^bStudy design did not permit calculation of absolute survival differences.

The structural answer to why rigorous trial evidence for exercise has been slow to accumulate is simple: skeletal muscle contraction is not patentable, generates no revenue, and has no sponsor. This misalignment between health benefit and financial incentive explains why a low-cost, host-directed therapy remains peripheral in a system otherwise exquisitely sensitive to return on investment.

Dosing and administration

The prevailing clinical approach of nonspecific advice to “stay active” lacks the rigor expected of any other systemic intervention. The maintenance regimen supported by epidemiological and trial data aligns with international consensus guidelines recommending regular moderate-intensity aerobic activity combined with resistance training.¹⁴ As with any systemic agent, dosing must be individualized. Pre-prescription screening for cardiopulmonary disease, musculoskeletal limitations, neuropathy, and frailty should be standard, with referral to rehabilitation or exercise oncology specialists where available.

Health equity and LMIC implementation

Cancer care in the Global South remains fundamentally impaired by the lack of foundational surveillance infrastructure and financial resources. These systemic deficits render entire populations invisible to the medical systems intended to serve them,¹⁵ creating a barrier that extends far beyond the mere cost of technology-dependent therapeutics. High-cost interventions frequently fail in these settings because they rely on the very administrative and logistical foundations that are currently absent.

The promise of Myokinib raises an unavoidable question: access for whom? Modern targeted therapies and immunotherapies face formidable implementation barriers in the Global South, including cold-chain logistics, procurement failures, and per-treatment costs that can exceed annual per capita income.¹⁶ Myokinib inverts this calculus. It requires no refrigeration, no import license, and no intravenous infusion suite. Its supply chain is, in principle, zero-mile.

Nevertheless, the implementation advantages are real. Unlike cytotoxic or targeted agents, Myokinib delivery can be task-shifted to non-physician providers. Community health workers embedded in primary care across sub-Saharan Africa, South Asia, and Latin America can be trained to prescribe, monitor, and reinforce exercise adherence using low-cost tools such as pedometers, mobile health reminders, and group-based walking programs.¹⁷ This model has proven effective for cardiovascular disease prevention and diabetes management in resource-limited settings; it can readily be adapted for cancer survivorship.

For oncology systems stretched beyond capacity, Myokinib offers something rare: a high-value adjunctive therapy that does not compete for constrained resources like infusion chairs, pharmacy budgets, or specialist time. For the millions of cancer survivors in LMICs who complete curative-intent treatment and return to communities with no survivorship infrastructure, it may be the only systemic adjunctive therapy realistically available. Failing to prescribe it is not therapeutic humility; it is forfeiture of benefit. By leveraging existing community health infrastructures, we can narrow survival gaps quickly, even in health systems with limited resources.

Guideline integration

Exercise lacks the delivery infrastructure that pharmaceuticals enjoy.⁷ If Myokinib is to function as a systemic therapeutic rather than discretionary advice, it must be embedded in the same infrastructure that governs chemotherapy, endocrine therapy, and targeted agents. This means moving beyond endorsement statements toward operational integration.

Three concrete steps could accelerate this transition. First, professional societies should incorporate explicit exercise prescriptions into disease-specific treatment pathways as quality metrics, tracked alongside chemotherapy completion rates. Second, EHR systems should include Myokinib in oncology order sets, with structured fields for dose, intensity, and adherence monitoring. Third, survivorship care plans should transition from passive recommendations to active prescriptions, supported by health system investment in behavioral infrastructure, prescribing Myokinib without access to qualified exercise professionals is analogous to prescribing medication without dispensing capacity. None of this requires new evidence. It requires reclassification: treating the existing evidence with the same seriousness accorded to pharmaceutical data of comparable quality. This operational shift parallels the trajectory of early palliative care, which was similarly shown to improve both quality of life and survival when reclassified from end-of-life comfort care to a standard, concurrent intervention across cancer diagnoses.^18,19

A predictable critique is that renaming exercise adds nothing substantive—that semantics do not alter physiology. We contend that in oncology, semantics are the architectural blueprint of care delivery. The classification of an intervention determines its destiny: therapies are dosed, tracked, and reimbursed; lifestyle behaviors are suggested, forgotten, and uncompensated. The failure to prescribe exercise is not a failure of evidence but a failure of categorization. History supports this view. The term 'financial toxicity,' introduced by Zafar and Abernethy in 2013,²⁰ did not discover a new phenomenon; it named one long ignored, and that single act catalyzed measurement tools, screening protocols, and policy change. By assigning exercise a pharmacological identity, we do not change the intervention; we convert a vague conversation into a discrete, trackable, and potentially reimbursable order. Until it is named, dosed, and classified as a systemic agent, exercise will remain what it has been for decades: universally recommended, rarely prescribed.

Conclusion

Reclassifying skeletal muscle contraction as Myokinib does not compete with pharmacologic innovation; it augments the oncology formulary. A safe, low-cost, host-directed therapy already exists. The failure to systematically prescribe it is not an evidence gap. It is a delivery gap, and delivery gaps are modifiable. Closing this one would represent a rare convergence of quality improvement, value-based care, and health equity, requiring no new molecules, no expanded budgets, and no regulatory approval. Only a decision to act.

Author contributions

Bibek Aryal (Conceptualization, Investigation, Supervision, Writing—original draft, Writing—review & editing)

Funding

None declared.

Conflicts of interest

None declared.

Data availability

Data sharing is not applicable to this article as no new datasets were generated or analyzed during the current study.